CasInvent Pharma is focused on developing innovative therapeutic options for treating resistant tumors through the use of highly selective inhibitors of the Casein Kinase 1 (CK1) family. Established in 2020 as a spin-off from Masaryk University, the company leverages proprietary research from leading experts in CK1 biology and chemistry. The CK1 inhibitors are designed to target specific isoforms of CK1, which play a crucial role in various cellular mechanisms that contribute to resistance against targeted therapies. The company aims to advance its candidate compounds into clinical trials for conditions such as Acute Myeloid Leukemia (AML) and solid tumors, including pancreatic ductal adenocarcinoma (PDAC), triple-negative breast cancer (TNBC), melanoma, and prostate cancer.

The research and development efforts at CasInvent Pharma are supported by a strong collaboration with academic institutions, particularly Masaryk University, where significant discoveries related to CK1 inhibitors have been made. The company has recently secured funding to enhance its portfolio of CK1 inhibitors, which have shown promising preclinical results in targeting hard-to-treat leukemias. This funding will facilitate the progression of their lead compounds towards clinical development, with the potential to offer novel treatment alternatives for patients facing high unmet medical needs in oncology.

Czechia (Czech Republic)

CasInvent Pharma is a drug development company focused on developing highly selective inhibitors of enzymes belonging to the casein kinase 1 (CK1) family for the treatment of selected malignancies. The company was established in 2020 as a spin-off company of Masaryk University in cooperation with the investment partner i&i Prague.

CasInvent Pharma

Company Details